| Objective: To investigate the efficacy and mechanism of jisheng shenqi pills combined with dapagliflozin in the treatment of diabetic nephropathy (DN) based on NOD-like receptor protein 3 (NLRP3) inflammasome. Methods: Random number table method was used, 140 patients with DN admitted to the Affiliated TCM Hospital Guangzhou Medical University from July 2020 to December 2021 were divided into control group (n=70, treated with dapagliflozin ) and study group (n=70, treated with jisheng shenqi pills combined with dapagliflozin). The scores of traditional chinese medicine syndrome, blood glucose indexes, renal function indexes, peripheral blood NLRP3 and related factors were compared between two groups. Results: The scores of difficult urination, fatigue and chills, edema, soreness and coldness of waist and knees, abdominal distension, pale complexion and morning diarrhea in study group were lower than those in control group after treatment (P<0.05). The fasting blood glucose (FBG), creatinine (SCr), 2h postprandial blood glucose (2hPG), urea nitrogen (BUN), glycosylated hemoglobin (HbA1c), NLRP3 messenger ribonucleic acid (mRNA) and cysteine protease 1 (Caspase-1) mRNA in study group were lower than those in control group.(P<0.05). Conclusion: Patients with DN are treated with jisheng shenqi pills combined with dapagliflozin, the clinical symptoms and blood glucose are effectively controlled, and improve renal function, which is speculated to be related to the inhibition of NLRP3 mRNA expression in peripheral blood mononuclear cells and the activation and amplification of downstream inflammatory pathways. |
